![Lawrence Kenyon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lawrence Kenyon
Financieel Directeur/CFO bij
OUTLOOK THERAPEUTICS, INC.
Vermogen: - $ op 31-05-2026
Profiel
Currently, Lawrence A. Kenyon is CFO, Secretary, Treasurer, Director, and Executive VP at Outlook Therapeutics, Inc. since 2015.
Formerly, served as President, CEO, CFO, and Secretary at Tamir Biotechnology, Inc. in 2013; Director at Tamir Biotechnology, Inc. in 2009; Chief Financial Officer and Executive Vice President at Endo Generics Holdings, Inc. from 2009 to 2010; Chief Financial Officer, Secretary, and EVP at NeoPharm, Inc. from 2000 to 2006; Chief Financial Officer at Par Pharmaceutical, Inc. from 2009 to 2010; and Chief Operating and Financial Officer at Arno Therapeutics, Inc. from 2014 to 2015.
Education includes an undergraduate degree from the University of Wisconsin, conferred in 1987.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 12-01-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
Actieve functies van Lawrence Kenyon
| Bedrijven | Functie | Begin |
|---|---|---|
| OUTLOOK THERAPEUTICS, INC. | Financieel Directeur/CFO | 18-06-2018 |
Eerdere bekende functies van Lawrence Kenyon
| Bedrijven | Functie | Einde |
|---|---|---|
| ARNO THERAPEUTICS, INC. | Financieel Directeur/CFO | 01-09-2015 |
Tamir Biotechnology, Inc.
 Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Engages in discovering and developing new class of therapeutic drugs | Algemeen Directeur | 31-03-2013 |
Par Pharmaceutical, Inc.
 Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets generic drugs and pharmaceuticals products | Financieel Directeur/CFO | 01-07-2010 |
| PAR PHARMACEUTICAL COMPANIES, INC. | Financieel Directeur/CFO | 04-06-2010 |
Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Engages in discovering and developing new class of therapeutic drugs | Financieel Directeur/CFO | 01-02-2009 |
Opleiding van Lawrence Kenyon
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
92
Eerstegraads connecties
7
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Engages in discovering and developing new class of therapeutic drugs | Health Technology |
Endo Generics Holdings, Inc.
 Endo Generics Holdings, Inc. Pharmaceuticals: GenericHealth Technology Operates as a holding company with interests in developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States | Health Technology |
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology Provides drug research, development and commercialization services | Health Technology |
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets generic drugs and pharmaceuticals products | Health Technology |
Arno Therapeutics, Inc.
 Arno Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs | Health Technology |
Outlook Therapeutics, Inc.
 Outlook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures bevacizumab therapeutic products | Health Technology |
